New hope for recurrent throat cancer: Radiation-Immunotherapy combo shows promise
NCT ID NCT07277764
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests a new approach for recurrent nasopharyngeal carcinoma (a type of throat cancer) that has come back after initial treatment and cannot be removed by surgery. The treatment combines a special radiation schedule (low and high doses) with an immunotherapy drug (anti-PD-1) to boost the immune system's attack on cancer cells. The study will enroll 23 participants and measure how well the cancer responds after 3 months, as well as long-term survival and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Anti-PD-1 monoclonal antibody (nivolumab or similar)
What this could lead to
If successful, this could offer a new treatment option for patients with recurrent nasopharyngeal carcinoma who cannot have surgery.
What could go wrong
This is a small, early-phase trial with only 23 participants, so results may not apply to everyone. The combination of radiation and immunotherapy may cause side effects like immune-related inflammation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA (NPC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jiangxi Cancer Hospital
RECRUITINGNanchang, Jiangxi, 330029, China
Contact Phone: •••-•••-•••• Email: •••••@•••••